Most Read Articles
Yen Yen Yip, 01 Sep 2012

For the first time, a randomized controlled trial has found the serotonin-norepinephrine reuptake inhibitor (SNRI) duloxetine to be effective against chronic neuropathic pain associated with taxane- or platinum-based chemotherapy. [ASCO 2012; abstract CRA 9013]

08 Nov 2017
In women with histories of sexual abuse, a low serum concentration of neuropeptide Y (NPY) is associated with psychogenic nonepileptic seizure (PNES), indicating its potential to be a future biomarker, a recent study suggests.

Regions of brain metastasis vary by breast cancer subtypes

25 Nov 2017
Radiologists interpret complex medical imaging to arrive at an accurate diagnosis

Different breast cancer subtypes appear to show different spatial distributions of brain metastasis (BM), with luminal type and human epidermal growth factor receptor 2 (HER2)-positive breast cancers showing BM dominance in the occipital lobe and cerebellum, suggests a recent study.

Brain magnetic resonance (MR) images of 100 breast cancer patients with confirmed BM were retrospectively analysed. Distribution patterns of BM were compared among and within groups, which were defined by biological subtype of the primary tumour.

In the study sample, 24 patients had triple-negative primary breast cancers (mean age at diagnosis 46.45±10.88 years), 48 were HER2-positive (mean age at diagnosis 49.5±11.45 years) and 28 had luminal breast cancer (mean age at diagnosis 46.75±9.73 years).

While the mean number of BM per patient did not differ among the subtypes (5.04±6.37, 4.71±6.58 and 5.35±6.69), both triple negative (23.5±23.36 months) and HER2-positive (19±29.54 months) cancers had significantly shorter time to BM than luminal breast cancers (42±45.51 months; p<0.01).

In intergroup analysis, researchers found that BM from triple-negative breast cancers was more likely to occur in the limbic region, parietal lobe and frontal lobe (corrected p<0.05) compared to the other cancer subtypes.

In contrast, HER2-positive breast cancers were less likely to have BM in the frontal lobe and subcortical regions, while BM from luminal type breast cancers were less likely to happen in the cerebellum, subcortical region and occipital lobe compared with the other cancer subtypes (corrected p<0.05).

Editor's Recommendations
Most Read Articles
Yen Yen Yip, 01 Sep 2012

For the first time, a randomized controlled trial has found the serotonin-norepinephrine reuptake inhibitor (SNRI) duloxetine to be effective against chronic neuropathic pain associated with taxane- or platinum-based chemotherapy. [ASCO 2012; abstract CRA 9013]

08 Nov 2017
In women with histories of sexual abuse, a low serum concentration of neuropeptide Y (NPY) is associated with psychogenic nonepileptic seizure (PNES), indicating its potential to be a future biomarker, a recent study suggests.